Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Omaha ENT Clinic
mi
from
Omaha, NE
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Omaha ENT Clinic
mi
from
Omaha, NE
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Children's Health Center / St. Elizabeth Medical Center
mi
from
Utica, NY
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Children's Health Center / St. Elizabeth Medical Center
mi
from
Utica, NY
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Haywood Pediatric and Adolescent Medicine Group, P.A.
mi
from
Clyde, NC
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Haywood Pediatric and Adolescent Medicine Group, P.A.
mi
from
Clyde, NC
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Sterling Research Group, LTD
mi
from
Cinncinati, OH
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Sterling Research Group, LTD
mi
from
Cinncinati, OH
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Urgent Care Specialists Hometown Urgent Care
mi
from
Columbus, OH
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Urgent Care Specialists Hometown Urgent Care
mi
from
Columbus, OH
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Central Ohio Clinical Research
mi
from
Columbus, OH
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Central Ohio Clinical Research
mi
from
Columbus, OH
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Carolina Ear, Nose and Throat Clinic
mi
from
Orangeburg, SC
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Carolina Ear, Nose and Throat Clinic
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Tanner Clinic
mi
from
Layton, UT
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Tanner Clinic
mi
from
Layton, UT
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Foothill Family Clinic South
mi
from
Salt Lake City, UT
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Foothill Family Clinic South
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Heartland Research Associates LLC - Augusta
mi
from
Salt Lake City, UT
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Heartland Research Associates LLC - Augusta
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Van Dorn Pediatrics
mi
from
Alexandria, VA
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Van Dorn Pediatrics
mi
from
Alexandria, VA
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Kern Allergy and Medical Research, Inc.
mi
from
Bakersfield, CA
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Kern Allergy and Medical Research, Inc.
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Central California Research
mi
from
Fresno, CA
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Central California Research
mi
from
Fresno, CA
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Pharma Research International, Inc
mi
from
Naples, FL
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Pharma Research International, Inc
mi
from
Naples, FL
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
SCORE Physician Alliance, LLC
mi
from
St. Petersburg, FL
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
SCORE Physician Alliance, LLC
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Kentucky Pediatric/ Adult Research
mi
from
Bardstown, KY
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Kentucky Pediatric/ Adult Research
mi
from
Bardstown, KY
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Valley Stream Pediatrics
mi
from
Valley Stream, NY
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Valley Stream Pediatrics
mi
from
Valley Stream, NY
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
PMG Research of Bristol, LLC
mi
from
Bristol, TN
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
PMG Research of Bristol, LLC
mi
from
Bristol, TN
Click here to add this to my saved trials
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated:  1/23/2017
Holston Medical Group, PC
mi
from
Kingsport, TN
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years
Status: Enrolling
Updated: 1/23/2017
Holston Medical Group, PC
mi
from
Kingsport, TN
Click here to add this to my saved trials
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
Status: Enrolling
Updated:  2/2/2017
SwedishAmerican Regional Cancer Center
mi
from
Rockford, IL
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
Status: Enrolling
Updated: 2/2/2017
SwedishAmerican Regional Cancer Center
mi
from
Rockford, IL
Click here to add this to my saved trials
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
Status: Enrolling
Updated:  2/2/2017
Mercy Health System
mi
from
Janesville, WI
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
Status: Enrolling
Updated: 2/2/2017
Mercy Health System
mi
from
Janesville, WI
Click here to add this to my saved trials
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
Status: Enrolling
Updated:  2/2/2017
University of Wisconsin
mi
from
Madison, WI
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
Status: Enrolling
Updated: 2/2/2017
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
Status: Enrolling
Updated:  2/2/2017
ProHealth Care, Inc
mi
from
Waukesha, WI
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer
Status: Enrolling
Updated: 2/2/2017
ProHealth Care, Inc
mi
from
Waukesha, WI
Click here to add this to my saved trials
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Pittsburg, PA
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Pittsburg, PA
Click here to add this to my saved trials
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Status: Enrolling
Updated:  2/2/2017
mi
from
Porte Alegre,
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Status: Enrolling
Updated: 2/2/2017
mi
from
Porte Alegre,
Click here to add this to my saved trials
Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)
Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)
Status: Enrolling
Updated:  2/8/2017
Georgia Prevention Institute
mi
from
Augusta, GA
Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)
Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)
Status: Enrolling
Updated: 2/8/2017
Georgia Prevention Institute
mi
from
Augusta, GA
Click here to add this to my saved trials
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated:  2/14/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated: 2/14/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Washington,
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Tampa, FL
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Chicago, IL
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
New Orleans, LA
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
New Orleans, LA
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Livingston, NJ
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Livingston, NJ
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Bronx, NY
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
New York, NY
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Harrisburg, PA
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Harrisburg, PA
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Charleston, SC
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Dallas, TX
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Fort Worth, TX
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
Richmond, VA
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated:  2/15/2017
mi
from
Linz,
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Status: Enrolling
Updated: 2/15/2017
mi
from
Linz,
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
Yale-New Haven Hospital
mi
from
New Haven, CT
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
Montefiore Medical Center
mi
from
New York, NY
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
Montefiore Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
Medication Therapy Management Combined With Drug and Gene Interaction Software and Cytochrome DNA Testing Among a Population of Polypharmacy Medicare Patients
Status: Enrolling
Updated:  2/22/2017
VRx Pharmacy Services
mi
from
Salt Lake City, UT
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
Medication Therapy Management Combined With Drug and Gene Interaction Software and Cytochrome DNA Testing Among a Population of Polypharmacy Medicare Patients
Status: Enrolling
Updated: 2/22/2017
VRx Pharmacy Services
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Randomized Controlled Trial Testing The Effect Of A Multi-Nutrient Fortified Juice
A Randomized Controlled Trial Testing the Effect of a Multi-nutrient Fortified Juice
Status: Enrolling
Updated:  2/27/2017
Boston Med Ctr
mi
from
Boston, MA
A Randomized Controlled Trial Testing The Effect Of A Multi-Nutrient Fortified Juice
A Randomized Controlled Trial Testing the Effect of a Multi-nutrient Fortified Juice
Status: Enrolling
Updated: 2/27/2017
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Single Embryo TrAnsfeR of Euploid Embryo
Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment
Status: Enrolling
Updated:  2/28/2017
Fertility Treatment Center
mi
from
Tempe, AZ
Single Embryo TrAnsfeR of Euploid Embryo
Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment
Status: Enrolling
Updated: 2/28/2017
Fertility Treatment Center
mi
from
Tempe, AZ
Click here to add this to my saved trials